Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
JANX Price/Volume Stats
| Current price | $9.20 | 52-week high | $19.83 |
| Prev. close | $8.81 | 52-week low | $5.65 |
| Day low | $8.56 | Volume | 87,000 |
| Day high | $9.29 | Avg. volume | 83,915 |
| 50-day MA | $9.77 | Dividend yield | N/A |
| 200-day MA | $10.74 | Market Cap | 424.75M |
JANX Stock Price Chart Interactive Chart >
JANX POWR Grades
- Sentiment is the dimension where JANX ranks best; there it ranks ahead of 84.61% of US stocks.
- JANX's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- JANX's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
JANX Stock Summary
- JANUX THERAPEUTICS INC's stock had its IPO on June 11, 2021, making it an older stock than just 6.83% of US equities in our set.
- With a price/sales ratio of 56.16, JANUX THERAPEUTICS INC has a higher such ratio than 96.86% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.13 for JANUX THERAPEUTICS INC; that's greater than it is for only 10.1% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to JANUX THERAPEUTICS INC are LYEL, KRON, PLRX, STOK, and PRAX.
- JANX's SEC filings can be seen here. And to visit JANUX THERAPEUTICS INC's official web site, go to www.januxrx.com.
JANX Valuation Summary
- In comparison to the median Healthcare stock, JANX's price/earnings ratio is 127.1% lower, now standing at -7.9.
- Over the past 31 months, JANX's price/sales ratio has gone down 2456.5.
Below are key valuation metrics over time for JANX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| JANX | 2023-12-29 | 58.5 | 1.4 | -7.9 | -8.0 |
| JANX | 2023-12-28 | 63.8 | 1.5 | -8.6 | -8.7 |
| JANX | 2023-12-27 | 59.3 | 1.4 | -8.0 | -8.1 |
| JANX | 2023-12-26 | 56.9 | 1.4 | -7.7 | -7.8 |
| JANX | 2023-12-22 | 57.6 | 1.4 | -7.8 | -7.9 |
| JANX | 2023-12-21 | 54.7 | 1.3 | -7.4 | -7.5 |
JANX Price Target
For more insight on analysts targets of JANX, see our JANX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $35.00 | Average Broker Recommendation | 1.38 (Strong Buy) |
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Latest JANX News From Around the Web
Below are the latest news stories about JANUX THERAPEUTICS INC that investors may wish to consider to help them evaluate JANX as an investment opportunity.
An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% UndervaluedKey Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity... |
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsSAN DIEGO, November 07, 2023--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights |
JANX Price Returns
| 1-mo | -15.98% |
| 3-mo | 52.32% |
| 6-mo | -26.87% |
| 1-year | -53.39% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -14.26% |
| 2023 | -18.53% |
| 2022 | -33.25% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...